Elebsiran and pegylated-IFNα: Progress toward a functional cure for chronic hepatitis B

JHEP Reports 2026 Open access

Read full text
Authors: Sara Battistella, Ulrike Protzer, Xavier Forns
DOI: 10.1016/j.jhepr.2026.101741
Cited by: 1
References: 7

Abstract

Functional cure, defined as sustained HBsAg loss 24 weeks after the end of treatment (EOT), remains the ultimate goal for patients with chronic hepatitis B (CHB).1 Achieving this endpoint requires: (1) suppression of viral replication, (2) cessation of viral protein production, and (3) restoration of HBV-specific immune responses. Combination regimens will likely be necessary to achieve both viral suppression and immune control.1

Fields of Study & Subjects

Hepatitis B Virus Studies Hepatitis C virus research Hepatitis Viruses Studies and Epidemiology

Publication details

Journal / source
JHEP Reports
Publisher
Elsevier BV
Volume
8
Issue
4
Pages
101741–101741
Publication date
26 February 2026
Language
EN